79617-89-3

Usage

Uses

Used in Pharmaceutical Industry:
Sertraline hydrochloride is used as an antidepressant medication for treating psychiatric disorders such as major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder.
Used in Cardiovascular Applications:
In the cardiovascular field, Sertraline hydrochloride is used as a treatment for hypotension occurring in disorders like neurocardiogenic syncope and idiopathic orthostatic hypotension, which are affected by autonomic dysfunction. It helps in improving blood pressure regulation and reducing symptoms associated with these conditions.

InChI:InChI=1/C17H17Cl2N.ClH/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11;/h2-6,8,10,12,17,20H,7,9H2,1H3;1H

Upstream product

• 140631-53-4 sertraline 
• 261776-41-4 (4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-ylidene)methylamine 
• 123-39-7 N-Methylformamide 
• 25596-28-5 N-methyl ammonium formate 
• 79560-19-3 4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one 
• 244263-56-7 trans-(1R,4S)(+)-N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthyl]-N-methyl formamide 
• 79836-45-6 trans-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine 

Downstream Products

• 79617-95-1 cis-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine 
• 254731-40-3 1S-cis-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine-mandelate 
• 1357380-69-8 (1S,4S)-sertraline*(S)-mandelic acid 
• 244223-89-0 (cis-1S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine (R)-mandelate 
• 880489-75-8 (1R,4R)-sertraline*(R)-mandelic acid 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF [4(S,R)-(3,4-DICHLOROPHENYL)-3,4-DIHYDRO-1(2H)-NAPHTHALEN-1-YLIDENE]METHYLAMINE

The present invention relates to a process for making substantially pure racemic sertraline or its pharmaceutically acceptable salts having a cis/trans ratio of greater than about 85: 15% and which is substantially free of its deschloro impurities. The pr

IMPROVED MANUFACTURING PROCEDURE FOR THE PREPARATION OF POLYMORPHIC FORM II OF CIS-(1S)-N-METHYL-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHLENEAMINE HYDROCHLORIDE (SERTRALINE HYDROCHLORIDE)

The present invention relates to the improved, scalable and efficient manufacturing procedure for the preparation of the antidepressant Cis-(1S)-N-Methyl-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-napthaleneamine hydro chloride, Sertraline Hydrochloride polymorphic form II. The present invention further relates to the improved and modified procedures for preparing, separating and isolating the key intermediates involved in the preparationof Sertraline Hydrochloride polymorphic form II. The present invention also further relates to the use of novel reagents or a combination thereof and new methodologies to prepare some o'f the key intermediates involved in the preparation of Polymorphic Form II of Sertraline Hydrochloride.

Process for converting trans-sertraline to cis-sertraline

A process for preparing sertraline hydrochloride includes reacting trans-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthaleneamine with a base in an aqueous basic organic solvent.

PROCESSES FOR THE PREPARATION OF SERTRALINE HYDROCHLORIDE

The invention relates to processes for the preparation of Schiff's base, and to the use of Schiff's base as intermediate in the preparation of naphthalenamine derivatives which are active compounds for treating the anxiety related disorders. The invention also relates to processes for the preparation of sertraline or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions that include the sertraline.

PROCESS FOR THE MANUFACTURE OF SERTRALINE

Process for the preparation of sertraline by reductive amination of racemic 4-(3, 4-dichlorophenyl)-3, 4-dihydro-1-(2H)-naphthalenone, carried out as one- reaction-vessel process without isolation of intermediates, in the form of pure separated cis and trans isomers, the way of conversion of trans isomer to cis isomer and preparation of FII polymorph of 1S-cis isomer from any other polymorph.